Compare Smith & Nephew plc (SNN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 4.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| SNN | VCSH | |
|---|---|---|
Market Cap | $11.10B | $51.90B |
Volume | 1,051,703 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $37.17 | $80.20 |
52-Week Low | $26.42 | $77.03 |
Typical Hold Time | 121 Days | 52 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
VCSH trades at $77.30 with minimal daily movement (+0.04%). The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights VCSH's competitive 4.5-4.8% dividend yield and low 0.03% expense ratio, though credit spreads remain tight. The ETF's short 2.7-year duration provides some protection against rising rates.
VCSH offers stable income exposure to investment-grade corporate bonds but faces headwinds from tight credit spreads and limited price appreciation potential. The fund's low duration minimizes interest rate risk, making it suitable for conservative investors seeking yield above Treasury alternatives, though corporate credit risk remains a consideration in economic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
